|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: TamoxifenFrom: ainsron@msn.comSat May 13 00:36:53 2000
The problem as I see it is that this lady has no contralateral breast, she now has no breasts at all! Is there still a benefit to taking tamoxifen, or are the risks of PE and endometrial cancer greater than any perceived benefit? >See the following ACOG publication: >Committee Opinion Number 224, October 1999 > >“Tamoxifen and the Prevention of Breast Cancer in High-Risk Women “ > >In part it says: > >“Tamoxifen's possible usefulness in preventing breast cancer was >suggested by several observations. First, studies showed that >tamoxifen-treated patients had a statistically significant lower >incidence of contralateral breast cancer. Second, in vitro and in vivo >animal studies showed that tamoxifen blocked the initiation and >progression of tumors and inhibited the growth of cancer cells by >several mechanisms. Third, a great deal of information was known about >the pharmacodynamics, metabolism, and antitumor effects of tamoxifen in >animals and humans . > >-- >John Hellriegel, MD, PhD >
-- Ronald E. Ainsworth, MD
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 04:46:29 2009 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.